Abstract: An optical device includes a first set of one or more electrodes, a second set of one or more electrodes distinct and separate from the first set of one or more electrodes, and a solution containing transparent metal ions in a liquid or gel electrolyte. The solution is located between the first set of one or more electrodes and the second set of one or more electrodes. The optical device may operate as an optical dimming device, which may be used in head-mounted display devices or as dimmable windows or shutters.

Abstract: Disclosed herein is a syringe pump module with a non-decoupling drive mechanism and motor actuation mechanism to configured to bidirectionally move the non-decoupling drive mechanism.

Abstract: A chip package and method for fabricating the same are provided that includes embedded off-die inductors coupled in series. One of the off-die inductors is disposed in a redistribution layer formed on a bottom surface of an integrated circuit (IC) die. The other of the series connected off-die inductors is disposed in a substrate of the chip package. The substrate may be either an interposer or a package substrate.

Abstract: The present invention belongs to the technical field of medicine, and relates in particular to a crystal form of a fibroblast growth factor receptor inhibitor shown in formula (I), and a preparation method therefor.

Abstract: A method and an equipment for preparing a pultruded polyurethane composite by a polyurethane pultrusion process, and the pultruded polyurethane composite obtained by the method and use thereof are provided.

Abstract: Disclosed herein are compositions and methods for treating subjects for pain with opioids while reducing or inhibiting their risk of opioid addiction.

Abstract: The present invention relates to a method for treating a cancer mediated by abnormality of multi-kinases, comprising administrating a compound as represented by formula (I) or a pharmaceutically acceptable salt and stereoisomer thereof, wherein R1, R2, X, Y, P, W, and Ar are as defined in the description. Also provided is a method for treating a cancer mediated by abnormality of multi-kinases, comprising administrating a crystal form I of a compound 4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-b]pyrido[4,3-e][1,4]diazepin-8-yl)morpholine, wherein in an X-ray powder diffraction pattern of crystal form I, there are characteristic peaks at 7.4±0.2°, 17.9±0.2°, 18.9±0.2°, 19.4±0.2°, 21.5±0.2°, and 23.7±0.2°.

Abstract: Disclosed herein is a syringe pump module with a non-decoupling drive mechanism and motor actuation mechanism to configured to bidirectionally move the non-decoupling drive mechanism.

Abstract: The present invention belongs to the pharmaceutical technical field, and specifically relates to a haloallylamine compound represented by formula I, a pharmaceutically acceptable salt, an ester or a stereoisomer thereof, R1, R2, R3, R4, R5, R6, L1, Cy1, R7 are defined as in the specification; the present invention also relates to pharmaceutical preparations and pharmaceutical compositions containing these compounds, and their use in preventing and/or treating the SSAO/VAP-1 protein-related or SSAO/VAP-1 protein-mediated disease.

Abstract: The present invention belongs to the technical field of medicines, relates to novel use of a multi-kinase inhibitor, and particularly relates to a compound of general formula (I) or a pharmaceutically acceptable salt, a stereoisomer and a crystal form thereof for use in the treatment of biliary tract cancer, a pharmaceutical composition comprising the compound, a method for treating biliary tract cancer by using the compound, use of the compound in the treatment of biliary tract cancer, and use of the compound in the preparation of a medicament for treating biliary tract cancer. The variables in the general formula are defined in the specification. Research shows that the multi-kinase inhibitor compound of general formula (I) or the pharmaceutically acceptable salt, the stereoisomer and the crystal form thereof have a treatment effect on biliary tract cancer, and especially on cholangiocarcinoma, so that the compound of the present invention has huge clinical application potential.

Abstract: Disclosed are a TAM family kinase/and Ron kinase inhibitor compound as shown in general formula (I), a pharmaceutically acceptable salt, an ester, a stereoisomer and a tautomer thereof, a pharmaceutical composition and a pharmaceutical preparation containing same, and the use thereof. The compound can selectively inhibit TAM family tyrosine kinase/and Ron kinase, and can be used for the treatment and/or prevention of diseases mediated by the abnormal expression of a receptor of TAM family kinase/and Ron kinase and/or a ligand thereof. By means of targeted inhibition of the TAM family kinase/and Ron kinase, the compound can reverse the immunosuppressive environment in a tumor microenvironment, inhibit the growth, migration and/or drug resistance performance of tumors, and exert anti-tumor immunological effects and anti-tumor efficacy. The definition of each group in the formula is described in the specification.

Abstract: The present invention falls within the technical field of medicine, and in particular relates to PDE9 inhibitor compounds as shown in formula (I) or pharmaceutically acceptable salts or stereoisomers thereof, and also relates to pharmaceutical preparations and pharmaceutical compositions of the compounds and the uses thereof. X1, X2, X3, X4, R1, R2, ring A, L and m are as defined in the description. The compounds can be used to prepare drugs for treating or preventing related diseases mediated by PDE9.

Abstract: Technologies are provided for validating expression updates. A change to an editable expression can be detected by a client computing device and an expression update describing the detected change can be transmitted to an application server over a bidirectional communication channel. The application server can analyze the expression update to determine whether the detected change resulted in a valid expression. Analyzing the expression update can comprise locating an entity identifier in the detected change and searching a database to determine whether the identified entity exists. The application server can also determine whether a given user has permission to access the identified entity. The application server can transmit expression update validation information back to the client computing device over the bidirectional communication channel. The client computing device can update a user interface displaying the expression based on the validation information.

Abstract: Disclosed are uses of a compound represented by general formula (I) and pharmaceutically acceptable salts, isomers and deuterated compounds thereof in the preparation of a medicine for treating heart failure diseases. Experiments prove that the compound can improve the heart function of rats with heart failure, reverse myocardial remodeling caused by heart failure, and reduce fibrosis in the marginal zone of infarction.

Abstract: The present invention relates to the technical field of pharmaceuticals, and particularly to a PDE9 inhibitor compound of formula (I) or a pharmaceutically acceptable salt, an isomer, a deuterated compound, a metabolite or a prodrug thereof. The present invention also relates to pharmaceutical formulations, pharmaceutical compositions and use thereof. X1, X2, X3, X4, R1, R2, ring A, L and m are as defined in the specification. The compound of the present invention can be used in the manufacture of a medicament for treating or preventing a PDE9-mediated related disease.

Abstract: A sous-vide circulator cooker that sounds an audible alarm when the system raises the temperature of the water to a determined temperature. The sous-vide circulator cooker includes temperature sensors, heaters and a pump to circulator temperature controlled fluids. The system also contains a speaker or buzzer that can play alarms or music when the system comes to a predetermined temperature. In at least one embodiment, the sous-vide circulator can also distinguish between self-heating and user-induced temperature changes, and will sound alarms accordingly.

Abstract: A sous-vide circulator cooker that sounds an audible alarm when the system raises the temperature of the water to a determined temperature. The sous-vide circulator cooker includes temperature sensors, heaters and a pump to circulator temperature controlled fluids. The system also contains a speaker or buzzer that can play alarms or music when the system comes to a predetermined temperature. In at least one embodiment, the sous-vide circulator can also distinguish between self-heating and user-induced temperature changes, and will sound alarms accordingly.